Last Updated : June 20, 2024
Details
FilesGeneric Name:
blinatumomab
Project Status:
Pending
Therapeutic Area:
Acute lymphoblastic leukemia, pediatrics
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0367-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Indicated for the pediatric patients with Philadelphia chromosome negative relapsed/refractory B precursor acute lymphoblastic leukemia (ALL) who are in first relapse.
Files
Last Updated : June 20, 2024